Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

The Phase I study GO42144 evaluates single agent GDC-6036 in advanced or metastatic solid tumors with KRAS G12C mutation. GDC-6036 is an oral, highly potent, and selective KRAS G12C inhibitor that irreversibly locks the protein in an inactive state to turn off its oncogenic signalling. This analysis shows that GDC-6036 has encouraging anti-tumor activity in patients with a variety of solid tumors with KRAS G12C mutation, an acceptable safety profile and a pharmacokinetics profile compatible with daily dosing.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

I am a healthcare professional

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically